Marketing Authorization Application submitted to European Medicines Agency for setmelanotide as treatment of pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency obesities

Setmelanotide is a melanocortin-4 receptor(MC4R) agonist. MC4R is part of key biological pathway regulating energy expenditure & appetite. POMC & LEPR deficiency obesities are ultra-rare genetic disorders, with patients suffering from insatiable hunger beginning at very young age


Biospace Inc.